Technical Analysis for 0QNO - Lonza Group AG
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New Uptrend | Bullish | 0.00% | |
Gapped Up | Strength | 0.00% | |
New Downtrend | Bearish | 1.84% | |
Gapped Up | Strength | -0.30% | |
Up 3 Days in a Row | Strength | -0.30% | |
New Uptrend | Bullish | 0.24% | |
Stochastic Buy Signal | Bullish | 0.24% | |
Gapped Down | Weakness | 0.24% | |
Lower Bollinger Band Touch | Weakness | 0.24% | |
Oversold Stochastic | Weakness | 0.24% |
Alert | Time |
---|---|
Up 2% | about 15 hours ago |
Rose Above Previous Day's High | about 19 hours ago |
10 DMA Support | about 20 hours ago |
Rose Above 10 DMA | about 20 hours ago |
Up 1% | about 20 hours ago |
Get a Trading Assistant
Lonza Group AG Description
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was incorporated in 1897 and is headquartered in Basel, Switzerland.
Classification
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 600.8985 |
52 Week Low | 308.3999 |
Average Volume | 69,674 |
200-Day Moving Average | 433.11 |
50-Day Moving Average | 498.06 |
20-Day Moving Average | 531.03 |
10-Day Moving Average | 519.29 |
Average True Range | 16.24 |
RSI (14) | 54.34 |
ADX | 32.43 |
+DI | 20.25 |
-DI | 19.34 |
Chandelier Exit (Long, 3 ATRs) | 512.48 |
Chandelier Exit (Short, 3 ATRs) | 543.82 |
Upper Bollinger Bands | 559.67 |
Lower Bollinger Band | 502.38 |
Percent B (%b) | 0.39 |
BandWidth | 10.79 |
MACD Line | 4.88 |
MACD Signal Line | 8.88 |
MACD Histogram | -4.0033 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 550.12 | ||||
Resistance 3 (R3) | 548.31 | 538.08 | 545.90 | ||
Resistance 2 (R2) | 538.08 | 531.64 | 538.98 | 544.50 | |
Resistance 1 (R1) | 531.46 | 527.67 | 534.77 | 533.26 | 543.09 |
Pivot Point | 521.23 | 521.23 | 522.89 | 522.13 | 521.23 |
Support 1 (S1) | 514.61 | 514.79 | 517.92 | 516.41 | 506.58 |
Support 2 (S2) | 504.38 | 510.81 | 505.28 | 505.18 | |
Support 3 (S3) | 497.75 | 504.38 | 503.77 | ||
Support 4 (S4) | 499.56 |